Navigation Links
ALK rearrangement found in nearly 10 percent of patients in Lung Cancer Mutation Consortium
Date:7/5/2011

ALK rearrangement has been found in 9.6% of lung cancer patients tested in the Lung Cancer Mutation Consortium, and MET amplification in another 4.1%, reflecting how many patients might benefit from targeted therapies such as crizotinib, according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer (IASLC).

The Lung Cancer Mutation Consortium (LCMC), involving 14 U.S. cancer centers, was established to evaluate genetic alterations in 1,000 patients with advanced lung adenocarcinoma.

CLIA-certified labs at each site are using multiplex assays to profile eight genes previously linked to lung cancer, AKT1, BRAF, EGFR, HER2, KRAS, MEK1, NRAS and PIK3CA. Two other genes, ALK and MET, have been tested by fluorescence in situ hybridization (FISH) for rearrangements or amplifications.

"High quality molecular diagnosis for multiple markers can be achieved in a reasonable period of time to select patients for targeted therapy," said Prof. Marileila Varella Garcia, Ph.D., a professor of medical oncology at the University of Colorado School of Medicine.

Put simply, ALK rearrangement occurs when the head (promoter) and tail (active domain) of the gene split. Either part may then fuse with another gene. When the active domain of ALK fuses with a hyperactive promoter such as the EML4 promoter, it creates a fusion oncogene that has been associated with non-small cell lung cancer.

Lung cancer patients with ALK rearrangement have been found in previous studies to respond well to crizotinib, an ALK inhibitor.

In the LCMC study, researchers looked for ALK fusion with EML4 (EML4-ALK) or other partners, and MET amplification. ALK rearrangement was detected in 9.6% of patients and MET amplification in 4.1%.

ALK mutations were associated with younger age, median 52.3 years; ALK negative subjects had a median age of just under 60 years. ALK positive subjects were more likely to be never-smokers than ALK negative subjects (64% vs. 31%), less likely to have smoked in the past (33% vs. 61%) and more likely to have experienced liver metastasis (21% vs. 8%). No association was found between ALK-positive status and sex, gender, stage or brain metastasis.


'/>"/>

Contact: Rene McGaw
renee.mcgaw@ucdenver.edu
31-205-493-413
International Association for the Study of Lung Cancer
Source:Eurekalert

Related medicine news :

1. NIH, USU study maps hotspots of genetic rearrangement
2. Scientists identify KRAS rearrangements in metastatic prostate cancer
3. The Samuel Waxman Cancer Research Foundation awards more than $3.1 million in grants
4. Autism Speaks and Flutie Foundation join HPs Hacking Autism to develop touch apps for autism
5. Massachusetts General Hospital, Iacocca Foundation announce promising results of Phase I diabetes trial
6. New genetic risk factors of lupus found in study of African-American women
7. Sleep switch found in fruit flies
8. The New York Stem Cell Foundation announces new initiative for Parkinsons disease
9. Damon Runyon Cancer Research Foundation awards $3.45 million to 9 top young clinical investigators
10. Possible susceptibility genes found in neurodegenerative disorder
11. SIR Foundation sets research priorities for minimally invasive treatments for MS patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... January 23, 2017 , ... ... institution’s inaugural K-20 Education Summit to be held March 23-25, 2017 in Tampa, ... Jan. 25, 2017. , The keynote speakers include Dr. Michelle R. Weise, executive ...
(Date:1/23/2017)... ... ... Wooden and plastic balance boards have been around since at least the 1950s and are ... the first and only balance board to use a patent-pending design featuring high-pressure inflation technology ... time as well as skill-level adjustable for all ages and abilities. The board can ...
(Date:1/23/2017)... SC (PRWEB) , ... January 23, 2017 , ... ... is the premiere organization in North America for the scientific development, healthcare training ... 2017 Annual Scientific Session, and its 2017 AAT Member Certification Qualification Courses for ...
(Date:1/23/2017)... ... January 23, 2017 , ... Moisture ... choosing the right method is paramount to success. Selecting an inappropriate measurement method ... where multiple persons use the same equipment. Rare or expensive substances are wasted ...
(Date:1/23/2017)... ... January 23, 2017 , ... Old School Labs™, makers ... Mr. Olympia Classic Physique bodybuilder Breon Ansley to its growing team of brand ambassadors. ... bodybuilder in 2012 and in less than a year was able to turn professional, ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... 2017 NeuroVive Pharmaceutical AB (Nasdaq Stockholm: ... preclinical collaboration agreement with the Children,s Hospital of ... M.D., a US key opinion leader in the mitochondrial medicine ... ... from NeuroVive,s research program, NVP015, in certain experimental disease models. ...
(Date:1/21/2017)... Research and Markets has announced the addition of ... Test (Tumor, Clinical Chemistry, Microbiology, Esoteric), By Type of Lab ... Cancer, HIV/AIDS etc.), Forecast to 2022" report to their ... ... especially clinical lab testing, which has evolved as a major ...
(Date:1/21/2017)... CAMBRIDGE, Mass. , Jan. 20, 2017 ... the Keystone Symposia Conference, "PI3K Pathways in ... Pharmaceuticals, Inc. (NASDAQ: INFI ... oral immuno-oncology development candidate that selectively inhibits ... is able to help overcome resistance to ...
Breaking Medicine Technology: